Medico Remedies Limited has informed the Exchange regarding Board meeting held on February 12, 2026.
MEDICO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts more than Nifty Microcap 250 and 1.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Medico Remedies' Board approved the unaudited standalone financial results for the quarter and nine months ended December 31, 2025. Q3 revenue from operations jumped to Rs 5,868.29 lakhs, up about 48.6% from Rs 3,948.99 lakhs in the same quarter last year. For the 9-month period, revenue grew roughly 36% YoY to Rs 14,956.96 lakhs. Net profit for Q3 stood at Rs 287.23 lakhs (vs Rs 261.97 lakhs YoY), while 9M PAT rose about 26% to Rs 725.86 lakhs. The statutory auditor Shah Shroff & Associates issued an unmodified limited review report, noting that the prior auditor M/s V J Shah & Co had reviewed the earlier part of FY26 and FY25. Q3 EPS came in at Rs 0.35 (not annualised).
Strong top-line growth of nearly 49% YoY in Q3 signals healthy demand expansion, though profit growth lagged revenue, suggesting some margin pressure. The change of statutory auditor to Shah Shroff & Associates is notable and worth monitoring, while the clean (unmodified) review report removes immediate audit-quality concerns for shareholders.